Pharmaceutical

IBI-343 by Innovent Biologics for Solid Tumor: Likelihood of Approval

IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor.

Jun 20, 2024 - 04:00
IBI-343 is under clinical development by Innovent Biologics and currently in Phase I for Solid Tumor.
Read the original article

Tags:

Previous Article

Anti-RANKL Monoclonal Antibody by Jiangsu Pacific Meinuoke Bio-Pharmarceutical f...

Next Article

IMA-203CD8 by Immatics for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Cara Therapeutics cuts 50% of staff and drops kidney disease program

Cara Therapeutics cuts 50% of staff and drops kidney di...

Jan 23, 2024

STAT+: HCA discloses massive data breach affecting 11 million patients

STAT+: HCA discloses massive data breach affecting 11 m...

Jul 10, 2023

Biden ‘continues to be fit for duty,’ his doctor says, after president undergoes annual physical

Biden ‘continues to be fit for duty,’ his doctor says, ...

Feb 29, 2024